Cryoablation Devices Market Size, Share, Growth, and Industry Analysis, By Type (Systems,Probes), By Application (Breast Cancer,Prostate Cancer,Cardiac Arrhythmia,Renal Cancer,Liver Cancer,Others), Regional Insights and Forecast to 2035

Cryoablation Devices Market Overview

The global Cryoablation Devices Market size is projected to grow from USD 631.43 million in 2026 to USD 747.62 million in 2027, reaching USD 2887.42 million by 2035, expanding at a CAGR of 18.4% during the forecast period.

Cryoablation devices are medical systems that employ extreme cold—often via liquid nitrogen, argon, or nitrogen gas—to freeze and necrose target tissues such as tumors, cardiac foci, or abnormal lesions. In 2024, the global cryoablation devices market was estimated at USD 459 million, with projections toward over USD 1,163 million by 2033. In 2024, the tissue contact probe ablator segment held ~45.2 % share of device usage, and cardiac arrhythmia applications commanded ~37.8 % share.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: ~32.2 % of global device share concentrated in North America
• Major Market Restraint: ~45.2 % share of devices are in tissue contact probe segment
• Emerging Trends: ~37.8 % of cryoablation uses are in cardiac arrhythmia
• Regional Leadership: North America held ~32.56 % revenue share in 2022
• Competitive Landscape: Boston Scientific leads after acquiring BTG, commanding major share
• Market Segmentation: Systems and probes comprise core share, ~80 % combined
• Recent Development: FDA issued recall on POLARx catheters due to esophageal injury events

Cryoablation Devices Market Latest Trends

The Cryoablation Devices Market is evolving under multiple converging trends. First, cardiac electrophysiology remains a key driver: in 2024, ~37.8 % of cryoablation procedures addressed atrial fibrillation, and the share of cryoballoon systems is rising compared to point-by-point cryocatheter use. Additionally, tissue contact probe ablator devices account for ~45.2 % share of device usage in 2024—reflecting their prominence in both oncology and arrhythmia treatments. There's also a migration toward miniaturized and imaging-guided cryoablation systems, with many devices incorporating real-time temperature sensors, ICE visualization compatibility, and integration with mapping systems. Hybrid applications combining cryo + radiofrequency or cryo + microwave protocols are being explored; some centers reported ~10–15 % improved lesion consistency using hybrid workflows.

Cryoablation Devices Market Dynamics

The Cryoablation Devices Market Dynamics are shaped by technological advancements, growing clinical acceptance, and the accelerating demand for minimally invasive therapies across oncology and cardiology. In 2024, more than 250,000 ablation procedures globally involved cryo-based systems, accounting for nearly 25 % of all thermal ablations performed that year. The integration of cryoablation into electrophysiology labs has surged, with cardiac arrhythmia procedures representing around 37.8 % of total utilization. Demand is also expanding within oncology, where cryoablation is used in approximately 15–20 % of small renal and liver tumor interventions worldwide.

DRIVER

"Rising prevalence of cardiac arrhythmias and increased adoption of minimally invasive ablation therapies."

Cardiac arrhythmias, especially atrial fibrillation, drive substantial demand for cryoablation devices. In 2021, CVD accounted for ~17.9 million deaths globally, with arrhythmias a key component. The shift toward minimally invasive approaches (cryo, RF, PFA) from open surgery accelerates growth. Many hospitals now prefer cryoballoon techniques owing to shorter procedure times and better safety profiles. Electrophysiology labs across North America and Europe report ~20–30 % year-on-year increases in cryoablation case volume. Further, the aging population in many developed nations means more patients eligible for ablation therapy; in the U.S., over 4 million diagnosed AF patients potentially benefit. As reimbursement frameworks mature and guideline adoption rises, more centers adopt cryoablation for arrhythmia, expanding the market.

RESTRAINT

"High costs, reimbursement constraints, and emerging alternative modalities."

Cryoablation systems bear high initial equipment and consumable costs—cryogenerators, probes, mapping interface, and disposables can strain budgets. Some institutions resist adoption due to budget constraints or limited procedural volume to amortize capital. There is also concern about inadequate reimbursement in some jurisdictions, which restricts adoption in smaller centers. Moreover, pulsed field ablation (PFA) is emerging: many electrophysiologists expect PFA to replace some cryo and RF uses, potentially cannibalizing cryo’s share. Surveys indicate they may shift >30 % of ablation cases to PFA within 12 months, reducing cryo demand. Safety recalls, such as esophageal injury linked to some cryo systems (e.g. POLARx recall events), erode clinician confidence. These financial, competitive, and safety pressures slow market penetration in mid-tier and developing markets.

OPPORTUNITY

"Expansion into oncology and hybrid applications, plus disposable probe models."

The market opportunity for cryoablation extends beyond cardiology into oncologic ablation—for renal, liver, lung, and breast tumors. Some centers report ~25 % annual growth in cryo usage for small renal lesions. Hybrid procedural products combining cryo + RF or cryo + microwave ablation protocols may capture middle-ground demand and improve lesion control. The development of disposable cryoprobes can reduce sterilization costs and lower barrier to access in smaller hospitals or clinics. Integration with imaging guidance (MRI or ultrasound + cryo) and AI-driven lesion prediction tools can boost procedural safety and efficiency. In emerging markets with increasing cancer burden and improving surgical infrastructure, there is scope for adoption of minimally invasive cryotherapy. Partnerships with oncology device manufacturers and expansion into pain, neurology, or prostate ablation use cases could broaden the market.

CHALLENGE

"Balancing freeze control, safety margins, and procedural consistency."

Achieving precise and safe cryo lesions is technically challenging. Tissue-specific thermal conduction, variable freezing dynamics, ice-ball size control, and thaw cycles require sophisticated control systems. Overfreezing risks collateral damage to adjacent structures such as nerves or the esophagus; underfreezing may lead to incomplete lesion causing recurrence. Clinicians demand predictable lesion depth across varying anatomies. Probe-tissue contact stability is critical; suboptimal contact leads to ineffective ablation—many centers report 5–10 % of cryoprobes underperforming in real use. Cryogen logistics, refill infrastructure, and system maintenance are burdensome for lower-volume centers. Ensuring device safety and efficacy across a broad anatomical range (e.g. heart, kidney, liver) requires rigorous validation. Risk of cooling gas leakage, cryoshock phenomena, or tissue hemorrhage adds clinical challenge. These technical, procedural, and safety constraints limit adoption and increase regulatory scrutiny.

Cryoablation Devices Market Segmentation

The Cryoablation Devices Market is segmented by type (Systems, Probes) and by application (Breast Cancer, Prostate Cancer, Cardiac Arrhythmia, Renal Cancer, Liver Cancer, Others). Systems include cryogenerators and console units; probes are the consumable ablation catheter or applicator. Application segmentation reflects use in tumor ablation and arrhythmia treatment. In 2024, cardiac arrhythmia comprised ~37.8 % of cryo usage, while oncology (renal, liver, prostate, breast) collectively accounted for ~51 %. Systems and probes together form over 80 % of device revenue. This segmentation drives Cryoablation Devices Market Analysis, Forecast, and Market Insights.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

• Systems: Systems—cryogenerators, console units, cooling hardware—serve as the backbone infrastructure. They constitute about 40 % of total system+probe revenue. A system’s reliability, cooling capacity, integration with mapping systems, and control algorithms differentiate providers. In advanced centers, multiple system upgrades are scheduled approximately every 5–7 years. Systems often come with service contracts covering ~20 % of device cost annually. Systems support multiple probe types (balloon, focal, spray) and often include safety redundancies. Because systems are capital-intensive, adoption is more prevalent in high-volume EP and hybrid labs.
• Probes: Cryoablation probes (balloon, focal, segmental, linear) constitute ~60 % of device revenue. Probes are often disposable or semi-reusable, driving recurring revenue. Use of cryoballoon probes is prevalent in AF ablation; in 2024, balloon probes accounted for over 50 % of probe use in EP cases. Advances in probe design include temperature sensing, better thermal conductivity, flexible shafts, and improved durability. Probe differentiation is critical for margins; many companies introduce specialty probes (slim, steerable, multiport) to command premium prices and lock-in customers.

BY APPLICATION

• Breast Cancer Application: Cryoablation in breast cancer treatment is emerging as a minimally invasive alternative to lumpectomy, offering precision tumor destruction with superior cosmetic outcomes. Approximately 5 % of global cryoablation procedures target breast lesions, primarily early-stage or benign tumors. Imaging-guided cryoablation—especially ultrasound and MRI-assisted systems—ensures accurate ice-ball control and minimal tissue trauma. Studies report over 90 % local control rates in tumors smaller than 2 cm, positioning this modality as an efficient outpatient procedure. Market expansion is supported by increased screening rates and demand for office-based therapies. Manufacturers are introducing single-use cryo probes with reduced cooling gas consumption, aligning with overall Cryoablation Devices Market Growth.
• Prostate Cancer Application: Cryoablation is increasingly utilized in the management of localized prostate cancer, with roughly 8 % share of total cryo applications. Its precision enables targeted gland ablation while sparing surrounding tissues, preserving urinary and sexual functions. In urology centers, focal cryo is preferred for patients unsuitable for radiation or surgery, with disease control rates exceeding 85 % in early-stage cases. Technological progress includes multi-probe systems that ensure uniform freeze zones and reduce recurrence risks. The global Cryoablation Devices Market Outlook in urology is strengthened by patient preference for less invasive procedures and shorter recovery times, making prostate cryo a significant long-term growth driver.
• Cardiac Arrhythmia Application: Cardiac arrhythmia—especially atrial fibrillation—remains the largest segment, accounting for nearly 37.8 % of all cryoablation procedures. Cryoballoon technology offers high procedural efficiency, reducing ablation times by up to 25 % compared to radiofrequency systems. In electrophysiology labs, cryo systems are used in over 80,000 cases annually worldwide. Clinical success rates for pulmonary vein isolation exceed 80 %, with markedly lower complication rates. Integration with real-time mapping systems enhances procedural accuracy. North America and Europe lead adoption due to established reimbursement and advanced infrastructure. These consistent outcomes continue to elevate cardiac cryo within Cryoablation Devices Market Analysis and drive long-term adoption in AF management.
• Renal Cancer Application: Cryoablation for renal cancer is well-established in treating small renal masses, representing about 10–12 % of total oncology cryo cases. It enables nephron-sparing interventions, ideal for patients unfit for partial nephrectomy. Clinical studies reveal local tumor control exceeding 85 % for lesions under 3 cm. Percutaneous cryo, guided by CT or MRI, offers reduced hemorrhage, lower postoperative pain, and shorter hospitalization times. Asia and Europe are expanding renal cryo infrastructure, supported by government-funded cancer programs. Cryo system innovations—such as dual-zone temperature regulation—enhance freeze precision and protect healthy tissue. These developments position renal applications as pivotal within the Cryoablation Devices Market Trends.
• Liver Cancer Application: Liver cryoablation is gaining prominence in treating hepatocellular carcinoma and metastatic lesions, accounting for nearly 9–10 % of total cryo applications globally. The technique enables uniform ice-ball formation, minimizing thermal injury and ensuring deeper lesion penetration. Real-time ultrasound and CT imaging integration have improved procedural accuracy by 20 %, while hybrid cryo-microwave techniques enhance ablation completeness. Leading hospitals in China, Japan, and the U.S. conduct thousands of hepatic cryo procedures annually. The therapy’s ability to treat inoperable or recurrent tumors supports its rising adoption. Continuous R&D investments and favorable clinical results reinforce liver cryo’s contribution to Cryoablation Devices Market Growth.
• Others Application: The “others” segment encompasses lung, thyroid, bone, and soft-tissue applications, collectively contributing 15–20 % of the total cryoablation volume. Lung and bone cryoablation, in particular, are expanding due to superior pain palliation and reduced morbidity versus conventional resection. Cryo-based interventional radiology procedures grew 25 % between 2021 and 2024, with over 600 hospitals worldwide offering image-guided cryo options. Portable and disposable cryo systems have made such interventions accessible in mid-tier facilities. Emerging applications, including nerve cryo for pain management, represent new revenue channels within the Cryoablation Devices Market Opportunities. Broader oncology use and technological miniaturization continue fueling growth across these diverse clinical domains.

Regional Outlook for the Cryoablation Devices Market

The Cryoablation Devices Market Regional Outlook reveals strong geographic disparities, driven by healthcare infrastructure, disease prevalence, and local manufacturing ecosystems. In 2024, North America accounted for approximately 32 – 40 % of total global device installations, followed by Europe at around 28 %, Asia-Pacific at roughly 25 %, and Middle East & Africa comprising the remaining 7 – 10 %.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

In North America, the Cryoablation Devices Market commands ~32.2 % to 40.7 % of global share in 2024–2025, representing the largest regional share. The U.S. leads with over USD 85.5 million in cryo device revenue in 2022 and holds about 22.9 % of global share. The region’s growth is supported by over 150 advanced electrophysiology (EP) labs performing cryoablation for atrial fibrillation. Cryoablation adoption in cardiology is strong, with many centers performing 500+ AF cryo cases annually. Oncology use (renal, liver, prostate cryo) is expanding with ~20 dedicated cryo centers in major hospital systems. Regulatory and reimbursement frameworks facilitate procedural adoption, and clinicians frequently participate in multicenter trials.

The North America Cryoablation Devices Market is projected at USD 186.6 million in 2025, rising to USD 828.8 million by 2034, capturing nearly 34.0 % of global market share with a CAGR of 18.4 %. Growth is fueled by advanced cardiac care centers, oncology infrastructure, and strong reimbursement frameworks across the United States and Canada. The region performs more than 90,000 cryoablation procedures annually, accounting for nearly 38 % of global utilization. Adoption is driven by high incidence of atrial fibrillation, breast, and prostate cancers, where cryoablation offers minimally invasive, cost-effective solutions. Strategic investments from major manufacturers and collaborations between hospitals and device companies are enhancing procedural accuracy, patient safety, and clinical efficiency.

North America – Major Dominant Countries in the Cryoablation Devices Market

• United States: The U.S. leads with market expansion from USD 150.0 million (2025) to USD 667.0 million (2034), representing 80.4 % regional share and CAGR 18.4 %, driven by over 70,000 annual cryoablation procedures and leading hospital-based technology adoption.
• Canada: Canada grows from USD 20.0 million to USD 88.0 million, securing 10.6 % regional share with CAGR 18.4 %, supported by national cancer programs and integration of cryotherapy in cardiac electrophysiology labs.
• Mexico: Mexico expands from USD 8.0 million to USD 36.0 million, holding 4.3 % share with CAGR 18.4 %, fueled by growing private hospital infrastructure and increased access to imported cryo systems.
• Puerto Rico: Puerto Rico grows from USD 4.0 million to USD 17.5 million, capturing 2.1 % share at CAGR 18.4 %, with demand concentrated in oncology and research applications.
• Bahamas: Bahamas increases from USD 4.6 million to USD 20.3 million, maintaining 2.6 % regional share and CAGR 18.4 %, driven by rising medical tourism and oncology-focused surgical centers.

EUROPE

Europe holds the second largest regional share of cryoablation device use. Key markets—Germany, U.K., France, Italy, Spain—drive oncology and cardiology use. Germany, for instance, supports numerous EP labs performing AF cryo, and leads in adopting hybrid cryo protocols in tumor ablation. The European public healthcare system favors minimally invasive therapies, spurring cryo adoption in cancer centers. Oncology cryo centers in Spain and Italy increasingly adopt cryo for renal, breast, and lung lesions. Many EU nations now include image-guided ablation (including cryo) in reimbursement lists. Clinical research networks in Europe conduct comparative trials of cryo vs RF or microwave ablation.

The Europe Cryoablation Devices Market is estimated at USD 144.0 million in 2025, reaching USD 650.4 million by 2034, holding approximately 26.7 % of global share with a CAGR of 18.4 %. Europe’s growth is propelled by robust public healthcare infrastructure, increased oncological R&D funding, and widespread adoption of cryoablation in cardiovascular therapy. More than 400 European hospitals have integrated cryo systems, with Germany, France, and the U.K. representing nearly 75 % of installations. Demand is bolstered by favorable reimbursement policies and the transition toward non-thermal ablation techniques in electrophysiology and oncology segments.

Europe – Major Dominant Countries in the Cryoablation Devices Market

• Germany: Germany expands from USD 40.0 million (2025) to USD 180.0 million (2034), accounting for 27.7 % share with CAGR 18.4 %, leading the region in cardiac cryo adoption, hybrid ablation programs, and oncology procedures performed across over 100 specialized hospitals with advanced cryotherapy infrastructure.
• United Kingdom: The U.K. grows from USD 30.0 million to USD 135.0 million, holding 20.7 % regional share at CAGR 18.4 %, supported by 60+ electrophysiology centers and research hospitals that utilize cryoablation for both cardiac arrhythmia and tumor therapy across public and private institutions.
• France: France expands from USD 25.0 million to USD 113.0 million, capturing 17.4 % share with CAGR 18.4 %, driven by breast, liver, and prostate cryo applications in major urban hospitals, including more than 50 clinical centers adopting cryo-based oncological interventions.
• Italy: Italy rises from USD 20.0 million to USD 90.0 million, maintaining 13.8 % share at CAGR 18.4 %, with increased usage in renal and cardiac interventions, supported by expanded healthcare spending and rising medical equipment installations across both public and academic facilities.
• Spain: Spain grows from USD 18.0 million to USD 81.0 million, securing 12.4 % share and CAGR 18.4 %, propelled by government-backed oncology programs, cryo-focused medical innovation, and growing adoption in 50+ regional hospitals integrating minimally invasive cryo procedures.

ASIA-PACIFIC

The Asia-Pacific region is becoming the fastest-growing cryoablation market. China, Japan, South Korea, India, and Southeast Asian nations are expanding cryo centers, especially in oncology and arrhythmia. China leads in device procurement and cancer incidence; many Chinese hospitals installed cryo systems in 2023–2025. Japanese centers are adopting cryo for small kidney and prostate tumors. South Korean EP labs increasingly use cryo in AF ablation. India’s growth is fueled by rising cancer prevalence, affordability drives, and expanding private hospitals.

The Asia Cryoablation Devices Market is projected at USD 160.0 million in 2025, growing to USD 731.6 million by 2034, representing approximately 30.0 % of global share with a CAGR of 18.4 %. Asia’s rapid expansion is driven by large patient populations, expanding healthcare infrastructure, and a rise in cancer and cardiac disorder prevalence. Over 500 hospitals across Asia have deployed cryo systems, primarily in China, Japan, and India, which together account for nearly 70 % of installations. The region’s adoption is further supported by rising government healthcare budgets, local manufacturing initiatives, and growing clinical awareness of minimally invasive cryotherapy for oncology and arrhythmia treatments.

Asia – Major Dominant Countries in the Cryoablation Devices Market

• China: China expands from USD 70.0 million (2025) to USD 320.0 million (2034), accounting for 43.7 % of regional share with CAGR 18.4 %, leading the Asia market in liver, kidney, and lung cryo oncology procedures across more than 150 advanced treatment centers nationwide.
• Japan: Japan grows from USD 40.0 million to USD 180.0 million, maintaining 24.6 % share with CAGR 18.4 %, supported by highly developed medical infrastructure, research-based clinical adoption, and extensive use of cryoablation in tertiary cardiac hospitals and cancer therapy facilities across Tokyo and Osaka.
• India: India rises from USD 25.0 million to USD 110.0 million, capturing 15.0 % regional share with CAGR 18.4 %, driven by large oncology patient volumes, increased local manufacturing of cryo devices, and adoption across 80+ tertiary hospitals offering minimally invasive cancer ablation services.
• South Korea: South Korea expands from USD 15.0 million to USD 68.0 million, holding 9.3 % share at CAGR 18.4 %, backed by cutting-edge cardiac cryo installations, advanced electrophysiology labs, and strong government support for next-generation cryo device imports and localized R&D.
• Australia: Australia grows from USD 10.0 million to USD 53.6 million, representing 7.4 % share with CAGR 18.4 %, driven by high cryo procedure penetration in oncology, favorable regulatory policies, and collaborative academic programs supporting cryotherapy research across Sydney and Melbourne medical institutes.

MIDDLE EAST & AFRICA

In Middle East & Africa, initial adoption of cryoablation is in tertiary care and private specialist hospitals in UAE, Saudi Arabia, Egypt, South Africa, and Israel. These centers adopt cryo for cardiac and oncologic cases, often supplementing RF or microwave systems. Supply challenges, high equipment cost, and limited local trained operators constrict uptake. However, government health authorities in Gulf states are funding advanced cardiac and cancer care infrastructure, creating opportunities for cryo deployment. Collaboration with global device vendors ensures service support.

The Middle East & Africa Cryoablation Devices Market is valued at USD 42.7 million in 2025, expected to reach USD 228.0 million by 2034, holding nearly 9.0 % of the global Cryoablation Devices Market with a CAGR of 18.4 %. Market expansion is supported by rapid healthcare modernization, growing incidence of oncological and cardiovascular disorders, and increasing accessibility to advanced ablation technologies. The region is witnessing significant adoption in tertiary care centers across the UAE, Saudi Arabia, South Africa, Egypt, and Qatar. Over 120 hospitals have implemented cryo systems regionally, primarily targeting cardiac arrhythmia and renal cancer therapies.

Middle East & Africa – Major Dominant Countries in the Cryoablation Devices Market

• United Arab Emirates: The UAE expands from USD 12.0 million (2025) to USD 60.0 million (2034), capturing 26.3 % of regional share with CAGR 18.4 %, driven by high-end hospital infrastructure, strong oncology program integration, and a rising influx of medical tourism patients seeking cryo-based cancer and cardiac care.
• Saudi Arabia: Saudi Arabia rises from USD 10.0 million to USD 51.0 million, maintaining 22.4 % share at CAGR 18.4 %, propelled by large-scale investments in advanced electrophysiology labs, increased cardiac arrhythmia treatment rates, and growing adoption of cryo systems in Riyadh and Jeddah healthcare facilities.
• South Africa: South Africa grows from USD 8.0 million to USD 39.0 million, holding 17.1 % regional share with CAGR 18.4 %, supported by expanding oncology centers, improved accessibility to cryo probes, and rising use of cryoablation for renal and hepatic tumor management across leading Johannesburg hospitals.
• Egypt: Egypt expands from USD 6.7 million to USD 33.0 million, representing 14.4 % of regional market share with CAGR 18.4 %, driven by government-backed oncology programs, improved interventional radiology capabilities, and adoption of cryo devices across more than 40 tertiary hospitals in Cairo and Alexandria.
• Qatar: Qatar grows from USD 6.0 million to USD 29.0 million, maintaining 12.8 % share at CAGR 18.4 %, led by increasing cryo-based cardiac ablation usage, national healthcare funding expansion, and the introduction of integrated oncology care pathways within public and private hospitals in Doha.

List of Top Cryoablation Devices Companies

• Medtronic Plc.
• METRUM CRYOFLEX Sp.
• BVM Medical Limited
• Sanarus Technologies
• Galil Medical Inc.
• CooperSurgical Inc.
• HealthTronics, Inc.
• ICECURE MEDICAL
• CPSI Biotech
• AtriCure, Inc.

Boston Scientific / Medtronic: leading in cryoablation with combined deep installed base, acquisition of BTG and leadership in electrophysiology devices

Galil Medical / ICECURE MEDICAL: strong niche position in cryo probes and oncology cryo, with notable clinical adoption

Investment Analysis and Opportunities

Investment in cryoablation devices is gaining traction across medical device venture capital and hospital capital planning. In recent years, companies have secured USD 20–50 million rounds to develop next-gen cryo platforms with real-time control, imaging integration, and disposable probes. Larger device manufacturers are acquiring niche cryo companies or technologies to expand their electrophysiology or oncology portfolios. There is opportunity for investment in disposable cryoprobes, which promise to reduce sterilization costs and procedural down-time—many firms foresee > 30 % of revenue from consumables. Imaging-guided cryo (e.g. MRI-compatible probes) is another attractive segment, with premium device margins.

New Product Development

Recent product developments in cryoablation devices emphasize precision, safety, and integration. In 2023, one manufacturer launched a next-gen cryoballoon with enhanced cooling uniformity and shorter freeze cycles, reducing procedure time by ~10 %. Another company introduced a steerable focal cryocatheter with integrated temperature and contact sensors to optimize lesion formation. In 2024, disposable cryoprobes with modular tip-swapping capability were introduced, enabling multi-lesion treatment with a single base catheter. Hybrid systems combining cryo + microwave modalities are under development; early prototypes showed ~15 % deeper lesion penetration in ex vivo models. Imaging-guided cryoprobes compatible with intracardiac echocardiography (ICE) or MRI allowed real-time lesion visualization in pilot studies.

Five Recent Developments

• In 2023, one major device firm recalled its POLARx cryoablation catheter due to esophageal injury reports, prompting design revisions and safety updates.
• In 2024, Boston Scientific acquired BTG’s cryoablation business, consolidating market leadership and expanding its installed base.
• In 2024, a startup commercialized a steerable, sensor-laden disposable cryocatheter capable of 360° lesion control.
• In 2025, a hybrid cryo + microwave ablation device prototype was successfully tested in liver tumor pig models, showing deeper lesion volume.
• In 2025, an MRI-compatible cryo probe was introduced in a limited human pilot, enabling real-time lesion imaging during renal and cardiac cryoablation procedures.

Report Coverage of Cryoablation Devices Market

The Cryoablation Devices Market Report offers comprehensive Cryoablation Devices Market Analysis, Market Trends, Market Forecast, Market Size, Market Share, Market Growth, Market Outlook, Market Insights, and Market Opportunities tailored to B2B stakeholders. It segments the market by Type (Systems, Probes) and Application (Breast Cancer, Prostate Cancer, Cardiac Arrhythmia, Renal Cancer, Liver Cancer, Others). Each segment is dissected by device usage volume, revenue share, growth drivers, and competitive dynamics. Regional coverage spans North America, Europe, Asia-Pacific, and Middle East & Africa, examining adoption patterns, regulatory environments, and infrastructure readiness. Top companies profiled include Medtronic / Boston Scientific, Galil Medical / IceCure, BVM Medical, Sanarus, ICECURE, CooperSurgical, and more, with analysis of product portfolios, R&D pipelines, geographic presence, and growth strategies.

Cryoablation Devices Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 631.43 Million in 2026
Market Size Value By	USD 2887.42 Million by 2035
Growth Rate	CAGR of 18.4% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Systems Probes By Application : Breast Cancer Prostate Cancer Cardiac Arrhythmia Renal Cancer Liver Cancer Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample